BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16539821)

  • 21. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.
    Kashif M; Qureshi A; Adil SN; Khurshid M
    J Pak Med Assoc; 2010 Jan; 60(1):64-5. PubMed ID: 20055286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment with rituximab in benign and malignant hematologic disorders in children.
    Giulino LB; Bussel JB; Neufeld EJ;
    J Pediatr; 2007 Apr; 150(4):338-44, 344.e1. PubMed ID: 17382107
    [No Abstract]   [Full Text] [Related]  

  • 23. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.
    Silverman GJ; Weisman S
    Arthritis Rheum; 2003 Jun; 48(6):1484-92. PubMed ID: 12794814
    [No Abstract]   [Full Text] [Related]  

  • 24. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.
    Gómez-Almaguer D; Solano-Genesta M; Tarín-Arzaga L; Herrera-Garza JL; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; Jaime-Pérez JC
    Blood; 2010 Dec; 116(23):4783-5. PubMed ID: 20841509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell depletion and repopulation in autoimmune diseases.
    Pers JO; Daridon C; Bendaoud B; Devauchelle V; Berthou C; Saraux A; Youinou P
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):50-5. PubMed ID: 18270858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
    Kotani T; Takeuchi T; Kawasaki Y; Hirano S; Tabushi Y; Kagitani M; Makino S; Hanafusa T
    Lupus; 2006; 15(10):683-5. PubMed ID: 17120596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.
    Aleem A
    Ann Saudi Med; 2008; 28(5):382-5. PubMed ID: 18779631
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic apheresis in autoimmune and rheumatic diseases.
    Koo AP
    J Clin Apher; 2000; 15(1-2):18-27. PubMed ID: 10767049
    [No Abstract]   [Full Text] [Related]  

  • 30. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus.
    Hundae A; Peskoe S; Grimsley E; Patel S
    South Med J; 2008 Sep; 101(9):943-4. PubMed ID: 18708978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab in the treatment of autoimmune haematological disorders.
    Garvey B
    Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B; Lindholm C; Pullerits R
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Galarza C; Valencia D; Tobón GJ; Zurita L; Mantilla RD; Pineda-Tamayo R; Rojas-Villarraga A; Rueda JC; Anaya JM
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
    Looney RJ
    Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
    Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
    Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.
    Rastetter W; Molina A; White CA
    Annu Rev Med; 2004; 55():477-503. PubMed ID: 14746532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies in the treatment of autoimmune cytopenias.
    Robak T
    Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of systemic autoimmune and inflammatory diseases with rituximab].
    Bussone G; Hachulla E; Sibilia J; Michel M; Godeau B; Guillevin L; Mouthon L
    Presse Med; 2009 May; 38(5):808-23. PubMed ID: 19297127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of rituximab in the management of refractory autoimmune cytopenia].
    Losa Frías V; García Sánchez AM; Ortiz Valentín I; González Vicent M; Velasco Arribas MR; Madero López L; Sevilla Navarro J
    An Pediatr (Barc); 2013 Jun; 78(6):398-404. PubMed ID: 23266244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.